Recombinant Human VSTM2B Fc Chimera Avi-tag Protein, CF

When Goat Anti-Human IgG Fc Antibody (G-102-C) is immobilized at 0.5 μg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human VSTM2B Fc Chimera Avi-tag (Catalog # AVI10060) that produces 50% of the optimal binding response is found to be approximately 1-10 ng/mL.

2 μg/lane of Biotinylated Recombinant Human VSTM2B Fc Chimera Avi-tag (Catalog # AVI10060) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-72 kDa and 120-144 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSTM2B Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1- 7.5 μg/mL Measured by its binding ability in a functional ELISA. When Goat Anti-Human IgG Fc Antibody (Catalog # G-102-C) is immobilized at 0.5 μg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human VSTM2B Fc Chimera Avi-tag (Catalog # AVI10060) that produces 50% of the optimal binding response is found to be approximately 1-10 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human VSTM2B protein
  

  Human VSTM2B (Ala29-Thr263) Accession # A6NLU5.2	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: A6NLU5.2
• N-terminal Sequence:

  Ala29

• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-72 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSTM2B Fc Chimera Avi-tag Protein, CF

• V-set and transmembrane domain-containing protein 2B
• VSTM2B

Background

V-set and transmembrane domain-containing protein 2B (VSTM2B) is a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily. There have been 8 VSTM family members identified and several have been shown to exhibit immunosuppressive activity (1). Human VSTM2B consists of an extracellular domain (ECD) with an Ig-like V-type domain, a transmembrane domain, and single amino acid (aa) in the cytoplasm. The mature ECD of human VSTM2B shares 86% and 85% aa sequence identity with mouse and rat VSTM2B, respectively. Currently, both the expression pattern and biological functions of VSTM2B remain unknown. Our in-house data show that VSTM2B inhibits the human T cell activation, including anti-CD3 induced IL-2, IFN-gamma secretion, and T cell proliferation. Our Avi-tag Biotinylated Recombinant VSTM2B features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide.  Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

Bioinformatics

• Uniprot:
  • A6NLU5.2()